Seminars in Oncology
Volume 33, Issue 6 , Pages 657-663 , December 2006

Adjuvant Hormonal Therapy for Premenopausal Women With Breast Cancer

  • Regina J. Brown
    • ,
  • Nancy E. Davidson

      Affiliations

    • Corresponding Author InformationAddress correspondence to Nancy E. Davidson, MD, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 409, Baltimore. MD 21231-1000.

References 

  1. Osborne CK. Adjuvant endocrine therapy. In:  Harris JR,  Lippman ME,  Morrow M, et al. editor. Diseases of the Breast. (ed 3). Philadelphia, PA, Lippincott: Williams, & Wilkins; 2004;p. 865–891
  2. Emens LA, Davidson NE. Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res. 2003;9:486S–494S
  3. Dellapasqua S, Colleoni M, Gelber RD, et al. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol. 2005;23:1736–1750
  4. Visvanathan K, Davidson NE. Adjuvant endocrine therapy: Controversies and perspectives. In:  Bonadonna G,  Hortobagyi GN,  Valagussa P editor. Textbook of Breast Cancer (A Clinical Guide to Therapy). (ed 3). New York, NY: Taylor & Francis; 2006;p. 205–223
  5. Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol. 2005;23:1644–1655
  6. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of randomized trials. Lancet. 2005;365:1687–1717
  7. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr. 2001;30:5–15
  8. Beatson GW. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet. 1896;2:104–107
  9. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Lancet Oncol. 2006;7:191–193
  10. Hughes LL, Gray RJ, Solin LF, et al. Efficacy of radiotherapy for ovarian ablation: Results of a breast intergroup study. Cancer. 2004;101:969–972
  11. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol. 2006;24:1045–1051
  12. Parulekar WR, Day AG, Ottaway JA, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5. J Clin Oncol. 2005;23:6002–6008
  13. Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet. 2000;355:1869–1874
  14. Fornier MN, Modi S, Panageas KS, et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104:1575–1579
  15. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–2313
  16. Robertson JF, Blamey RW. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Eur J Cancer. 2003;39:861–869
  17. Kaufmann M, Jonat W, Blamey R, et al. Survival analyses from the ZEBRA study (Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer). Eur J Cancer. 2003;39:1711–1717
  18. Thomson CS, Twelves CJ, Mallon EA, et al. Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status. Breast. 2002;11:419–429
  19. Schmid P, Untch M, Wallwiener D, et al. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: Preliminary results of the TABLE study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate). Anticancer Res. 2002;22:2325–2332
  20. Castiglione-Gertsch M, O’Neill A, Price KN, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst. 2003;95:1833–1846
  21. Ejlertsen B, Mouridsen HT, Jensen M-B, et al: Ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: Similar efficacy from a randomized comparison in premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol (in press)
  22. Boccardo F, Rubagott A, Amoroso E, et al. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol. 2000;18:2718–2727
  23. Roche H, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann Oncol. 2006;17:1221–1227
  24. Roche H, Mihura J, de Lafontan B, et al. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node and receptor positive breast cancer patients: A randomized trial with a 7 year median followup. Proc Am Soc Clin Oncol. 1996;15:117;(abstr)
  25. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—Austrian Breast and Colorectal Cancer Study Group 5. J Clin Oncol. 2002;20:4621–7462
  26. Davidson NE, O’Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188). J Clin Oncol. 2005;23:5973–5982
  27. Arriagada R, Le MG, Spielmann M, et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol. 2005;16:389–396
  28. Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in premenopausal patients with early breast cancer: Results from the ZIPP study. Eur J Cancer. 2006;42:895–904
  29. Love RR, Duc NB, Allred DC, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol. 2002;20:2559–2566
  30. Love RR, Duc NB, Havighurst TC, et al. Her-2neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol. 2003;21:453–457
  31. Robert N, Wang M, Wood W, et al. Phase III comparison of tamoxifen with ovarian ablation in premenopausal women with axillary node negative receptor positive breast cancer <3 cm. Proc Am Soc Clin Oncol. 2003;22:16a;(abstr)
  32. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569–1583
  33. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826
  34. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–3734
  35. Thewes B, Meiser B, Taylor A, et al. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Ocnol. 2005;23:5155–5165
  36. Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004;22:4174–4183
  37. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal breast cancer: Status report 2004. J Clin Oncol. 2005;23:619–629

 Supported in part by National Institutes of Health Grant No. CA88843, and by the Pearl M. Stetler Research Fund Award.

PII: S0093-7754(06)00325-3

doi: 10.1053/j.seminoncol.2006.08.014

Seminars in Oncology
Volume 33, Issue 6 , Pages 657-663 , December 2006

Article Tools

* Image Usage & Resolution